It was too late. Andor Katona, an ancient immortal warrior, had fought his last battle, just as his lifemate arrived to save him. As he lies dying he realizes she is surrounded by danger and hopes his brothers will arrive in time to save her.
Lorraine Peters has seen enough of death. And she’s willing to fight death to have him. With wits, courage and new friends to help her she might survive this attack and those that are coming. But, even if Andor survives, the fight is far from over.
From #1 New York Times bestselling author Christine Feehan. Find our more at https//www.christinefeehan.com Romance, horror, paranormal
It was too late. Andor Katona, an ancient immortal warrior, had fought his last battle, just as his lifemate arrived to save him. As he lies dying he realizes she is surrounded by danger and hopes his brothers will arrive in time to save her.
Lorraine Peters has seen enough of death. And she’s willing to fight death to have him. With wits, courage and new friends to help her she might survive this attack and those that are coming. But, even if Andor survives, the fight is far from over.
From #1 New York Times bestselling author Christine Feehan. Find our more at https//www.christinefeehan.com Romance, horror, paranormal
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
Sammy the frog explains QROPS pension transfers for British expats so that they no longer have to pay tax upon death of 55% and avoid UK income taxes of 50%. Making light of a serious issue. This funny looking frog explains the gist of a pension transfer for British expatriates living abroad.
US Army Captain Dale Morton is a magician soldier—a “craftsman.” After a black-ops mission gone wrong, Dale is cursed by a Persian sorcerer. Major Michael Endicott, a Puritan craftsman, finds gruesome evidence that the evil Mortons have returned, and that Dale might be one of them. Meanwhile, Dale uncovers treason in the Pentagon’s highest covert ranks. As he hunts for his enemies before they can murder him, Endicott pursues Dale, divided between his duty to capture a rogue soldier and his desire to protect Dale from his would-be assassins. Together, they will discover that the demonic horrors that have corrupted American magic are not bound by family, or even death itself.
American Craftsmen by Tom Doyle find out more at http://us.macmillan.com/americancraftsmen/TomDoyle. Fantasy, Military
Just like people, dogs have their good days and bad days but for the 4.7 million dog bite victims each year, a dogs’ bad day can result in serious injury or even death. In 2012, State Farm® had 3,670 dog bite claims and paid more than $108 million as a result of dog bites. This is a slight decrease compared to the number of dog bite claims in 2011 (3,750 claims) and a slight decrease in the amount paid as a result of dog bite claims in 2011 ($109 million).
To view Multimedia News Release, go to http://www.multivu.com/mnr/56916-state-farm-usps-avma-national-dog-bite-prevention-week
Cancer is the leading cause of death by disease in children from ages 1 to 19 in the U.S. Yet, childhood cancer research and services are vastly and consistently underfunded. This weekend, Northwestern Mutual financial professionals and employees will support the fight against childhood cancer through its nonprofit partner, Alex’s Lemonade Stand Foundation (ALSF), by holding nearly 200 lemonade stands as part of the Foundation’s national fundraising initiative, Alex’s Lemonade Days (June 12-14).
Founded by Alex Scott (1996-2004) in 2004, Alex’s Lemonade Days is a three-day national event that grew out of Alex’s front yard lemonade stand. During Alex’s Lemonade Days, dedicated volunteers host thousands of Alex’s Lemonade Stands across the country, raising more than $1 million for childhood cancer research. June 2015 will mark the 12th Annual Lemonade Days, and will continue Alex’s mission to raise money one cup of lemonade at a time, renewing her idea that any contributor, at any age, can make a difference.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7422153-northwestern-mutual-lemonade-days/
November is National Alzheimer’s Disease Awareness Month, a time to focus on finding ways to prevent the disease and enrich the lives of millions of Americans who live with, or care for, someone with Alzheimer’s. Brookdale, a leading owner and operator of senior living solutions throughout the United States, has a long-standing commitment to support research to reduce the impact of Alzheimer’s, which is the sixth leading cause of death in the United States.
To view Multimedia News Release, go to http://www.multivu.com/players/English/64011-brookdale-senior-living-alzheimer-awareness/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Jean Cartwright Rhodes is struggling to come to grips with the death of her childhood best friend, Hope.
Twenty-nine years later, Jean fights for her sanity as she confronts the dark web of intrigue set in motion by
a split-second decision in the aftermath of the tragedy. Learn more here, http://bit.ly/1jXhhry Fiction, Thriller, Crime, Mystery
